about
Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A14-Aminopyridyl-Based CYP51 Inhibitors as Anti- Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo PotencyDiverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51A Single Center Experience for Antifungal Prophylaxis in Patients with Acute Myelogenous Leukemia.Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous AdministrationOropharyngeal Candidosis in HIV-Infected Patients-An Update.
P2860
Q27677470-D2C946A3-2449-4EA2-AF49-E46B291CED8FQ27684956-754906E6-06F1-4065-A5F9-C762DDFFEB46Q28481694-B443C733-0FE2-4B5C-BE77-107CB60240A7Q35736934-3D3D7FB2-87E8-465C-AD3E-E89519851093Q36917768-69D5DBC8-4FD2-43AF-A43F-B4A4E66BB9D1Q38193337-3930189B-6C6E-413C-BFFC-B6B706F8E777Q39593613-4EF70427-D77E-437F-92F3-C52C7967BDA4Q55371002-CC3E96BD-1F84-4F77-BAED-3CB1CD40F726
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Posaconazole: when and how? The clinician's view.
@en
Posaconazole: when and how? The clinician's view.
@nl
type
label
Posaconazole: when and how? The clinician's view.
@en
Posaconazole: when and how? The clinician's view.
@nl
prefLabel
Posaconazole: when and how? The clinician's view.
@en
Posaconazole: when and how? The clinician's view.
@nl
P2093
P2860
P1433
P1476
Posaconazole: when and how? The clinician's view.
@en
P2093
Aspasia Katragkou
Fotini Tsikopoulou
Theoklis E Zaoutis
P2860
P304
P356
10.1111/J.1439-0507.2011.02061.X
P577
2011-07-18T00:00:00Z